These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 29089726)

  • 1. The Use of Idarucizumab for Dabigatran Reversal in Clinical Practice: A Case Series.
    Goriacko P; Yaghdjian V; Koleilat I; Sinnett M; Shukla H
    P T; 2017 Nov; 42(11):699-703. PubMed ID: 29089726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Idarucizumab: A Review as a Reversal Agent for Dabigatran.
    Syed YY
    Am J Cardiovasc Drugs; 2016 Aug; 16(4):297-304. PubMed ID: 27388764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Idarucizumab for Reversal of Dabigatran-Associated Bleeding: Misnomer or Miracle?
    Miller L; Ferreira JA; Tucker C
    J Emerg Med; 2017 Mar; 52(3):341-347. PubMed ID: 27727040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Idarucizumab: First Global Approval.
    Burness CB
    Drugs; 2015 Dec; 75(18):2155-61. PubMed ID: 26578027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Idarucizumab for Dabigatran Reversal in the Management of Patients With Gastrointestinal Bleeding.
    Van der Wall SJ; Lopes RD; Aisenberg J; Reilly P; van Ryn J; Glund S; Elsaesser A; Klok FA; Pollack CV; Huisman MV
    Circulation; 2019 Feb; 139(6):748-756. PubMed ID: 30586692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Idarucizumab for Dabigatran Reversal.
    Pollack CV; Reilly PA; Eikelboom J; Glund S; Verhamme P; Bernstein RA; Dubiel R; Huisman MV; Hylek EM; Kamphuisen PW; Kreuzer J; Levy JH; Sellke FW; Stangier J; Steiner T; Wang B; Kam CW; Weitz JI
    N Engl J Med; 2015 Aug; 373(6):511-20. PubMed ID: 26095746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lessons learnt from local real-life experience with idarucizumab for the reversal of dabigatran.
    Brennan Y; Favaloro EJ; Pasalic L; Keenan H; Curnow J
    Intern Med J; 2019 Jan; 49(1):59-65. PubMed ID: 29869387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of Dabigatran-Associated Bleeding with Two Doses of Idarucizumab Plus Hemodialysis.
    Marino KK; Santiago RA; Dew RB; Berliner N; Connors JM; Connell NT; Tucker JK
    Pharmacotherapy; 2016 Oct; 36(10):e160-e165. PubMed ID: 27581709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. idarucizumab (PRAXBIND°). Don't rely too heavily on this dabigatran antidote.
    Prescrire Int; 2016 Nov; 25(176):260-263. PubMed ID: 30715821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects.
    Reilly PA; van Ryn J; Grottke O; Glund S; Stangier J
    Am J Med; 2016 Nov; 129(11S):S64-S72. PubMed ID: 27569674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The first experience with dabigatran antidote in the University Hospital Pilsen].
    Šlechtová J; Hajšmanová Z; Lavičková A; Šigutová P
    Cas Lek Cesk; 2016; 155(8):442-444. PubMed ID: 28098476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial.
    Glund S; Stangier J; Schmohl M; Gansser D; Norris S; van Ryn J; Lang B; Ramael S; Moschetti V; Gruenenfelder F; Reilly P; Kreuzer J
    Lancet; 2015 Aug; 386(9994):680-90. PubMed ID: 26088268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment.
    Eikelboom JW; van Ryn J; Reilly P; Hylek EM; Elsaesser A; Glund S; Pollack CV; Weitz JI
    J Am Coll Cardiol; 2019 Oct; 74(14):1760-1768. PubMed ID: 31582135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Idarucizumab for Reversal of Dabigatran-Associated Anticoagulation.
    Yogaratnam D; Ditch K; Medeiros K; Doyno C; Fong JJ
    Ann Pharmacother; 2016 Oct; 50(10):847-54. PubMed ID: 27389324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran.
    Sié P
    Drug Des Devel Ther; 2016; 10():1683-9. PubMed ID: 27274201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence supporting idarucizumab for the reversal of dabigatran.
    Pollack CV
    Am J Emerg Med; 2016 Nov; 34(11S):33-38. PubMed ID: 27697436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence Supporting Idarucizumab for the Reversal of Dabigatran.
    Pollack CV
    Am J Med; 2016 Nov; 129(11S):S73-S79. PubMed ID: 27568285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of patients post reversal with idarucizumab.
    Raco V; Ahuja T; Green D
    J Thromb Thrombolysis; 2018 Nov; 46(4):466-472. PubMed ID: 30120649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Idarucizumab for Reversing Dabigatran-Induced Anticoagulation: A Systematic Review.
    Thibault N; Morrill AM; Willett KC
    Am J Ther; 2018; 25(3):e333-e338. PubMed ID: 27175894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversal of dabigatran requiring hemodialysis, fresh frozen plasma, and 2 doses of idarucizumab in a patient with acute kidney injury.
    Sheikh-Taha M
    Am J Health Syst Pharm; 2019 Jan; 76(1):9-12. PubMed ID: 31381100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.